<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02632812</url>
  </required_header>
  <id_info>
    <org_study_id>GDN 025/14</org_study_id>
    <nct_id>NCT02632812</nct_id>
  </id_info>
  <brief_title>Gastrointestinal Integrity After Naproxen + Rebamipide Versus Naproxen + Placebo</brief_title>
  <official_title>Double-blind Trial on the Gastrointestinal Integrity Evaluation After Daily Naproxen 1100 mg + Rebamipide 200mg for 7 Days Versus Naproxen 1100mg + Placebo for 7 Days</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biolab Sanus Farmaceutica</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biolab Sanus Farmaceutica</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a double-blind, placebo-controlled, randomized, parallel trial to evaluate if
      rebamipide reduces the number of gastric events caused by naproxen. Sample size is 24
      participants (12 per treatment group), male or female, aged 18 years-old and above.

      Primary objective is to compare rebamipide effervescent granules 100 mg twice daily, plus
      naproxen (coated tablets) 550 mg twice daily to placebo plus naproxen 550 mg twice daily, for
      seven days, in reduction of gastric events caused by naproxen. Secondary objective is to
      evaluate safety and tolerability of rebamipide after multiple administrations.

      Participants will receive either rebamipide + naproxen or placebo + naproxen, as above,
      during 7 consecutive days, which will be accompanied by a follow-up visit.

      Gastric integrity will be assessed, before and after treatment, by endoscopy, with stomach
      biopsies and detection of H. pylori. Additionally, detection of occult blood in the stool
      will be performed, before and after treatment.

      From the above-mentioned biopsies, dosage of prostaglandin E2 and histopathological analysis
      will be performed.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Actual">November 2014</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Endoscopic Score - Cryer Score</measure>
    <time_frame>8 days</time_frame>
    <description>Cryer score according to gastroduodenal mucosal injury:
0 = Normal or erythema
= Any amount of submucosal hemorrhage or edema without erosions
= 1 erosion +- submucosal hemorrhage or edema
= 2-4 erosions +- submucosal hemorrhage or edema
= 5 or more erosions and/or a single ulcer +- submucosal hemorrhage or edema
= Multiple ulcers +- submucosal hemorrhage or edema - Ulcer</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Endoscopic Score - Modified Lanza Score</measure>
    <time_frame>8 days</time_frame>
    <description>Modified Lanza score according to gastroduodenal mucosal injury:
0 = No hemorrhage or erosion observed
= One or two hemorrhages or erosions observed in one gastric area
= Three to five hemorrhages or erosions observed in one gastric area
= Hemorrhages or erosions observed in two gastric areas, six or more hemorrhages or erosions observed in one gastric area, with the total number not exceeding ten in the entire stomach
= Hemorrhages or erosions observed in three or more gastric areas; eleven or more hemorrhages or erosions observed widely in the entire stomach
= Ulcer</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Histopathological Score</measure>
    <time_frame>8 days</time_frame>
    <description>Histopathologic grade score developed for microscopic injury evaluation 0 = Normal gastric mucosa or mild chronic inflammation
= Chronic gastritis without activity
= Chronic gastritis with activity on antrum
= Chronic gastritis with activity on the body
= Chronic gastritis with activity on antrum and on the body</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Intragastric pH</measure>
    <time_frame>8 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Presence of H. Pylori by Biopsy</measure>
    <time_frame>8 days</time_frame>
    <description>Giemsa stain was used to diagnose H. pylori (positive = presence of H. pylori)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Prostaglandin Level (PGE2 Quantification)</measure>
    <time_frame>8 days</time_frame>
    <description>Tissue prostaglandin concentration quantified by enzyme-linked immunosorbent assay (ELISA) using Cayman Chemical Monoclonal Prostaglandin E2 EIA Kit (item number 514010)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Adverse Events</measure>
    <time_frame>60 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Gastrointestinal Lesions</condition>
  <arm_group>
    <arm_group_label>Rebamipide &amp; Naproxen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rebamipide 100 mg effervescent granules (oral) Twice daily (total dose = 200 mg) for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo &amp; Naproxen</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sugar pill manufactured to mimic Rebamipide 100 mg effervescent granules (oral) Twice daily for 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rebamipide effervescent granules</intervention_name>
    <description>Rebamipide effervescent granules 100mg (oral), twice daily for 7 days</description>
    <arm_group_label>Rebamipide &amp; Naproxen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo effervescent granules</intervention_name>
    <description>Placebo effervescent granules (oral), twice daily for 7 days</description>
    <arm_group_label>Placebo &amp; Naproxen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naproxen tablet</intervention_name>
    <description>Naproxen tablet 550mg (tablet), twice daily for 7 days</description>
    <arm_group_label>Rebamipide &amp; Naproxen</arm_group_label>
    <arm_group_label>Placebo &amp; Naproxen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female study participants, aged 18 years-old and above; women cannot be
             pregnant or breastfeeding;

          -  Body mass index (BMI) greater than or equal to 19 and less than or equal to 28.75
             Kg/m2;

          -  Good health conditions or without significant diseases, according to best medical
             judgement, according to protocol requirements and study evaluations: medical history,
             blood pressure and heart rate measurements, physical examination, electrocardiogram
             (ECG) and screening laboratory tests;

          -  Ability to understand the nature and objectives of the trial, including risks and
             adverse events; willingness to cooperate with the researcher and proceed according to
             all study requirements, which shall be confirmed by Informed Consent Form signature.

        Exclusion Criteria:

          -  Known hypersensitivity to the investigational products (naproxen or rebamipide) or
             chemically related compounds; history of serious adverse reactions or hypersensitivity
             to any drug;

          -  Subject does not present intact superior gastrointestinal mucosa, i.e., presenting
             bleeding, ulcers and apparent injuries in baseline endoscopy;

          -  Subject has achlorhydria (intragastric pH &gt; 6.5);

          -  History or presence of hepatic or gastrointestinal diseases, or other condition that
             interferes with drug absorption, distribution, excretion or metabolism;

          -  Chronic therapy with any drugs, except oral contraceptives;

          -  History of hepatic, kidney, lungs, gastrointestinal, epileptic, hematologic or
             psychiatric disease; hypotension or hypertension, of any etiology, that requires
             pharmacological treatment; history of myocardial infarction, angina and/or heart
             failure;

          -  Occult blood in the stool before treatment;

          -  Electrocardiographic findings that, at investigator criteria, are not recommended for
             study participation;

          -  Deviations on screening laboratory results that are considered as clinically relevant
             by the principal investigator;

          -  History of drugs and alcohol addiction or excessive alcohol consumption (&gt; 35 g/day);

          -  Use of regular medications within 2 weeks prior study enrollment or use of any
             medications within one week prior to study enrollment, except oral contraceptives or
             cases which, based on drug's or metabolite's half-life, complete elimination can be
             assumed;

          -  Treatment, within 6 months before the trial, with any drugs known to have a
             well-established toxic potential to major organs;

          -  Participation in any other experimental research or administration of any experimental
             drug within 6 months before this trial;

          -  Any condition, according to investigator's best judgement, that prevents the subject
             to participate in the trial;

          -  Pregnancy, labor or miscarriage with 12 weeks before admission predicted date.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilberto De Nucci, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Galeno Desenvolvimento de Pesquisas Ltda.</affiliation>
  </overall_official>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 23, 2015</study_first_submitted>
  <study_first_submitted_qc>December 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 17, 2015</study_first_posted>
  <results_first_submitted>March 18, 2016</results_first_submitted>
  <results_first_submitted_qc>January 31, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 20, 2017</results_first_posted>
  <last_update_submitted>January 31, 2017</last_update_submitted>
  <last_update_submitted_qc>January 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naproxen</mesh_term>
    <mesh_term>Rebamipide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Rebamipide 200 mg</title>
          <description>Rebamipide 100 mg effervescent granules (oral) Twice daily (total dose = 200 mg)
Rebamipide effervescent granules
Naproxen tablet</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo effervescent granules (oral) Twice daily
Placebo effervescent granules
Naproxen tablet</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Rebamipide 200 mg</title>
          <description>Rebamipide 100 mg effervescent granules (oral) Twice daily (total dose = 200 mg)
Rebamipide effervescent granules
Naproxen tablet</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo effervescent granules (oral) Twice daily
Placebo effervescent granules
Naproxen tablet</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23.5" lower_limit="18" upper_limit="49"/>
                    <measurement group_id="B2" value="28.5" lower_limit="19" upper_limit="49"/>
                    <measurement group_id="B3" value="24.5" lower_limit="18" upper_limit="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Brazil</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Endoscopic Score - Cryer Score</title>
        <description>Cryer score according to gastroduodenal mucosal injury:
0 = Normal or erythema
= Any amount of submucosal hemorrhage or edema without erosions
= 1 erosion +- submucosal hemorrhage or edema
= 2-4 erosions +- submucosal hemorrhage or edema
= 5 or more erosions and/or a single ulcer +- submucosal hemorrhage or edema
= Multiple ulcers +- submucosal hemorrhage or edema - Ulcer</description>
        <time_frame>8 days</time_frame>
        <population>All recruited volunteers completed the trial.</population>
        <group_list>
          <group group_id="O1">
            <title>Rebamipide &amp; Naproxen</title>
            <description>Rebamipide 100 mg effervescent granules (oral) Twice daily (total dose = 200 mg) for 7 days
Rebamipide effervescent granules: Rebamipide effervescent granules 100mg (oral), twice daily for 7 days
Naproxen tablet: Naproxen tablet 550mg (tablet), twice daily for 7 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo &amp; Naproxen</title>
            <description>Sugar pill manufactured to mimic Rebamipide 100 mg effervescent granules (oral) Twice daily for 7 days
Placebo effervescent granules: Placebo effervescent granules (oral), twice daily for 7 days
Naproxen tablet: Naproxen tablet 550mg (tablet), twice daily for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Endoscopic Score - Cryer Score</title>
          <description>Cryer score according to gastroduodenal mucosal injury:
0 = Normal or erythema
= Any amount of submucosal hemorrhage or edema without erosions
= 1 erosion +- submucosal hemorrhage or edema
= 2-4 erosions +- submucosal hemorrhage or edema
= 5 or more erosions and/or a single ulcer +- submucosal hemorrhage or edema
= Multiple ulcers +- submucosal hemorrhage or edema - Ulcer</description>
          <population>All recruited volunteers completed the trial.</population>
          <units>Cryer score</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="0" upper_limit="5"/>
                    <measurement group_id="O2" value="4" lower_limit="0" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Endoscopic Score - Modified Lanza Score</title>
        <description>Modified Lanza score according to gastroduodenal mucosal injury:
0 = No hemorrhage or erosion observed
= One or two hemorrhages or erosions observed in one gastric area
= Three to five hemorrhages or erosions observed in one gastric area
= Hemorrhages or erosions observed in two gastric areas, six or more hemorrhages or erosions observed in one gastric area, with the total number not exceeding ten in the entire stomach
= Hemorrhages or erosions observed in three or more gastric areas; eleven or more hemorrhages or erosions observed widely in the entire stomach
= Ulcer</description>
        <time_frame>8 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rebamipide &amp; Naproxen</title>
            <description>Rebamipide 100 mg effervescent granules (oral) Twice daily (total dose = 200 mg) for 7 days
Rebamipide effervescent granules: Rebamipide effervescent granules 100mg (oral), twice daily for 7 days
Naproxen tablet: Naproxen tablet 550mg (tablet), twice daily for 7 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo &amp; Naproxen</title>
            <description>Sugar pill manufactured to mimic Rebamipide 100 mg effervescent granules (oral) Twice daily for 7 days
Placebo effervescent granules: Placebo effervescent granules (oral), twice daily for 7 days
Naproxen tablet: Naproxen tablet 550mg (tablet), twice daily for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Endoscopic Score - Modified Lanza Score</title>
          <description>Modified Lanza score according to gastroduodenal mucosal injury:
0 = No hemorrhage or erosion observed
= One or two hemorrhages or erosions observed in one gastric area
= Three to five hemorrhages or erosions observed in one gastric area
= Hemorrhages or erosions observed in two gastric areas, six or more hemorrhages or erosions observed in one gastric area, with the total number not exceeding ten in the entire stomach
= Hemorrhages or erosions observed in three or more gastric areas; eleven or more hemorrhages or erosions observed widely in the entire stomach
= Ulcer</description>
          <units>Modified Lanza score</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" lower_limit="0" upper_limit="5"/>
                    <measurement group_id="O2" value="4" lower_limit="0" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Histopathological Score</title>
        <description>Histopathologic grade score developed for microscopic injury evaluation 0 = Normal gastric mucosa or mild chronic inflammation
= Chronic gastritis without activity
= Chronic gastritis with activity on antrum
= Chronic gastritis with activity on the body
= Chronic gastritis with activity on antrum and on the body</description>
        <time_frame>8 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rebamipide &amp; Naproxen</title>
            <description>Rebamipide 100 mg effervescent granules (oral) Twice daily (total dose = 200 mg) for 7 days
Rebamipide effervescent granules: Rebamipide effervescent granules 100mg (oral), twice daily for 7 days
Naproxen tablet: Naproxen tablet 550mg (tablet), twice daily for 7 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo &amp; Naproxen</title>
            <description>Sugar pill manufactured to mimic Rebamipide 100 mg effervescent granules (oral) Twice daily for 7 days
Placebo effervescent granules: Placebo effervescent granules (oral), twice daily for 7 days
Naproxen tablet: Naproxen tablet 550mg (tablet), twice daily for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Histopathological Score</title>
          <description>Histopathologic grade score developed for microscopic injury evaluation 0 = Normal gastric mucosa or mild chronic inflammation
= Chronic gastritis without activity
= Chronic gastritis with activity on antrum
= Chronic gastritis with activity on the body
= Chronic gastritis with activity on antrum and on the body</description>
          <units>Histopathologic grade score</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Basal endoscopy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="0" upper_limit="4"/>
                    <measurement group_id="O2" value="1" lower_limit="0" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of treatment endoscopy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="0" upper_limit="4"/>
                    <measurement group_id="O2" value="1" lower_limit="0" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Intragastric pH</title>
        <time_frame>8 days</time_frame>
        <population>Intragastric PH measurement was not performed and for this reason it will not be available.</population>
        <group_list>
          <group group_id="O1">
            <title>Rebamipide &amp; Naproxen</title>
            <description>Rebamipide 100 mg effervescent granules (oral) Twice daily (total dose = 200 mg) for 7 days
Rebamipide effervescent granules: Rebamipide effervescent granules 100mg (oral), twice daily for 7 days
Naproxen tablet: Naproxen tablet 550mg (tablet), twice daily for 7 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo &amp; Naproxen</title>
            <description>Sugar pill manufactured to mimic Rebamipide 100 mg effervescent granules (oral) Twice daily for 7 days
Placebo effervescent granules: Placebo effervescent granules (oral), twice daily for 7 days
Naproxen tablet: Naproxen tablet 550mg (tablet), twice daily for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Intragastric pH</title>
          <population>Intragastric PH measurement was not performed and for this reason it will not be available.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Presence of H. Pylori by Biopsy</title>
        <description>Giemsa stain was used to diagnose H. pylori (positive = presence of H. pylori)</description>
        <time_frame>8 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rebamipide &amp; Naproxen</title>
            <description>Rebamipide 100 mg effervescent granules (oral) Twice daily (total dose = 200 mg) for 7 days
Rebamipide effervescent granules: Rebamipide effervescent granules 100mg (oral), twice daily for 7 days
Naproxen tablet: Naproxen tablet 550mg (tablet), twice daily for 7 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo &amp; Naproxen</title>
            <description>Sugar pill manufactured to mimic Rebamipide 100 mg effervescent granules (oral) Twice daily for 7 days
Placebo effervescent granules: Placebo effervescent granules (oral), twice daily for 7 days
Naproxen tablet: Naproxen tablet 550mg (tablet), twice daily for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Presence of H. Pylori by Biopsy</title>
          <description>Giemsa stain was used to diagnose H. pylori (positive = presence of H. pylori)</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Basal endoscopy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of treatment endoscopy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Prostaglandin Level (PGE2 Quantification)</title>
        <description>Tissue prostaglandin concentration quantified by enzyme-linked immunosorbent assay (ELISA) using Cayman Chemical Monoclonal Prostaglandin E2 EIA Kit (item number 514010)</description>
        <time_frame>8 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rebamipide &amp; Naproxen</title>
            <description>Rebamipide 100 mg effervescent granules (oral) Twice daily (total dose = 200 mg) for 7 days
Rebamipide effervescent granules: Rebamipide effervescent granules 100mg (oral), twice daily for 7 days
Naproxen tablet: Naproxen tablet 550mg (tablet), twice daily for 7 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo &amp; Naproxen</title>
            <description>Sugar pill manufactured to mimic Rebamipide 100 mg effervescent granules (oral) Twice daily for 7 days
Placebo effervescent granules: Placebo effervescent granules (oral), twice daily for 7 days
Naproxen tablet: Naproxen tablet 550mg (tablet), twice daily for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Prostaglandin Level (PGE2 Quantification)</title>
          <description>Tissue prostaglandin concentration quantified by enzyme-linked immunosorbent assay (ELISA) using Cayman Chemical Monoclonal Prostaglandin E2 EIA Kit (item number 514010)</description>
          <units>pg/mL (mean tissue PGE2 concentration)</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Basal PGE2 concentration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="999" lower_limit="890" upper_limit="1108"/>
                    <measurement group_id="O2" value="1005" lower_limit="876" upper_limit="1134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of treatment PGE2 concentration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="168" lower_limit="155" upper_limit="181"/>
                    <measurement group_id="O2" value="241" lower_limit="200" upper_limit="282"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Adverse Events</title>
        <time_frame>60 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rebamipide &amp; Naproxen</title>
            <description>Rebamipide 100 mg effervescent granules (oral) Twice daily (total dose = 200 mg) for 7 days
Rebamipide effervescent granules: Rebamipide effervescent granules 100mg (oral), twice daily for 7 days
Naproxen tablet: Naproxen tablet 550mg (tablet), twice daily for 7 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo &amp; Naproxen</title>
            <description>Sugar pill manufactured to mimic Rebamipide 100 mg effervescent granules (oral) Twice daily for 7 days
Placebo effervescent granules: Placebo effervescent granules (oral), twice daily for 7 days
Naproxen tablet: Naproxen tablet 550mg (tablet), twice daily for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Adverse Events</title>
          <units>adverse events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Rebamipide 200 mg</title>
          <description>Rebamipide 100 mg effervescent granules (oral) Twice daily (total dose = 200 mg)
Rebamipide effervescent granules
Naproxen tablet</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo effervescent granules (oral) Twice daily
Placebo effervescent granules
Naproxen tablet</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Addominal distress</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Heartburn</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gilberto De Nucci, PhD, principal investigator</name_or_title>
      <organization>Galeno Desenvolvimento de Pesquisas Ltda.</organization>
      <phone>55.19.32516928</phone>
      <email>denucci@gilbertodenucci.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

